CAH: Specialty and generics growth, strategic M&A, and disciplined investment drive strong outlook
Strong FY 2026 results were driven by specialty and generics, with FY 2027 guidance above long-term targets. Growth is supported by acquisitions, robust specialty and nuclear businesses, and disciplined capital allocation, while AI and cost optimization remain key priorities.Based on Cardinal Healt…